MARKET

NTLA

NTLA

Intellia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

23.51
+1.06
+4.72%
After Hours: 23.51 0 0.00% 17:30 09/18 EDT
OPEN
23.62
PREV CLOSE
22.45
HIGH
23.90
LOW
22.85
VOLUME
2.46M
TURNOVER
--
52 WEEK HIGH
25.56
52 WEEK LOW
9.18
MARKET CAP
1.38B
P/E (TTM)
-10.2364
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile

Analyst Price Target

The average NTLA stock price target is 30.41 with a high estimate of 57.50 and a low estimate of 16.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NTLA
Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Intellia Therapeutics Inc stock information, including NASDAQ:NTLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTLA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NTLA stock methods without spending real money on the virtual paper trading platform.